Business Context and Reporting Period
This Form 8-K was filed by TRxADE HEALTH, INC. (not Scienture Holdings, Inc.) on January 8, 2024. The report details an amendment to a previously completed merger agreement with Superlatus, Inc., which closed on July 31, 2023.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the adjustment of equity consideration related to the Superlatus merger.
Material Changes Versus Prior Period
The primary material change is the reduction of equity consideration owed to Superlatus shareholders due to the failure to meet a post-closing condition regarding the acquisition of Prestige Farms, Inc.
- Original Merger Consideration: 30,821,941 shares of Company common stock (valued at $7.30/share), comprised of 136,441 common shares and 306,855 Series B preferred shares (100:1 conversion).
- Adjusted Merger Consideration: 1,712,328 shares of Company common stock (valued at $7.30/share), comprised of 136,441 common shares and 15,759 Series B preferred shares (100:1 conversion).
- Share Surrender: Superlatus shareholders agreed to surrender 289,731 shares of the Company's Series B preferred stock back to the Company.
- Company Equity Value Adjustment: Adjusted to 12,500,000.
Guidance, Outlook, and Management Commentary
Management indicated that the Company will provide reasonable assistance and cooperation for any future acquisition or financing transactions proposed by Superlatus. Upon the consummation of such a transaction, the Company will issue shares of stock to Superlatus shareholders. All other terms of the original Merger Agreement remain in full force and effect.
Important Facts for Investor Verification
- Verify the exact number of Series B preferred shares surrendered (289,731) and the remaining balance held by Superlatus shareholders.
- Confirm the status of the failed post-closing condition regarding the acquisition of Prestige Farms, Inc.
- Review the full text of Amendment No. 1 (Exhibit 10.1) for any additional covenants or conditions not summarized in the 8-K.
- Monitor future filings for the issuance of new shares should Superlatus consummate a new transaction.